Table 2. Characteristics of responders to immunotherapy.
|
Expressiona
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age | Sex | T | N | G | Histological type | Metastatic site | Bcl-2 | Fas | Treatment | Best response (duration, mos) | Follow up (mos) | Status at last follow-up |
| 1 | 56 | M | 3b | 0 | 1 | Clear cell | Lung | −/− | −/− | IL-2 | PR (3) | 14 | DOD |
| 2 | 37 | M | 3a | 1 | 2 | Clear cell | Lung | −/+ | −/− | IL-2 | PR (9) | 50 | DOD |
| 3 | 61 | M | 1a | 0 | 1 | Clear cell | Lung | −/− | −/− | IFN-α +5FU | PR (7) | 106 | AWD |
| 4 | 68 | M | 3a | 0 | 2 | Clear cell | Lung | −/− | +/− | IL-2 | PR (10) | 125 | NEDb |
| 5 | 66 | F | 1b | 0 | 2 | Clear cell | Lung | −/− | −/− | IFN-α + (5FU → TU) | PR (49) | 100 | AWD |
| 6 | 54 | M | 3a | 0 | 3 | Papillary | Liver | −/NA | −/NA | IFN-α | PR (2) | 2 | DOC |
| 7 | 53 | M | 3a | 0 | 2 | Clear cell | Lung | −/NA | −/NA | IFN-α | CR (33) | 62 | DOD |
| 8 | 62 | F | 3b | 2 | 3 | Clear cell | Lung, LN | −/NA | −/NA | IL-2+IFN-α+TU | CR (28) | 30 | NED |
AWD=alive with disease; CR=complete response; DOC=died of other causes; DOD=died of disease; 5FU=5-fluorouracil; IFN=interferon; IL=interleukin; LN=mediastinal lymph node; mos=months; NA=not available; NED=no evidence of disease; PR=partial response; TU=tegafur uracil.
a
Expression of primary site/metastatic site.
b
No evidence of disease after resection of lung metastasis.